Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMPRSS4 | Q9NRS4 | 10/20 | 0.72 |
| ▸ | P2RX1 | P51575 | 16/20 | 0.66 |
| ▸ | P2RX7 | Q99572 | 6/20 | 0.66 |
| ▸ | P2RX4 | Q99571 | 5/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | IKBKB | O14920 | 1/20 | 0.62 |
| ▸ | CHUK | O15111 | 1/20 | 0.62 |
| ▸ | KDR | P35968 | 1/20 | 0.62 |
| ▸ | FLT3 | P36888 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | MYLK | Q15746 | 1/20 | 0.62 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.62 |
| ▸ | HNF4A | P41235 | 1/20 | 0.55 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.52 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL131425 | 0.84 | TMPRSS4 (0.77) | TMPRSS4P2RX1P2RX7P2RX4MEN1 | |
| SCHEMBL134235 | 0.84 | TMPRSS4 (1.00) | TMPRSS4P2RX1P2RX7P2RX4MEN1 | |
| SCHEMBL128984 | 0.83 | TMPRSS4 (0.69) | TMPRSS4P2RX1P2RX7P2RX4MEN1 | |
| SCHEMBL131701 | 0.81 | P2RX1 (0.71) | TMPRSS4P2RX1P2RX7P2RX4MEN1 | |
| SCHEMBL127962 | 0.80 | P2RX1 (1.00) | TMPRSS4P2RX1P2RX7P2RX4MEN1 | |
| SCHEMBL130439 | 0.80 | P2RX1 (0.81) | TMPRSS4P2RX1P2RX7P2RX4MEN1 | |
| SCHEMBL131786 | 0.80 | P2RX1 (0.74) | TMPRSS4P2RX1P2RX7P2RX4MEN1 | |
| SCHEMBL23388964 | 0.79 | P2RX1 (0.67) | TMPRSS4P2RX1P2RX7P2RX4MEN1 | |
| SCHEMBL130063 | 0.79 | P2RX1 (0.67) | TMPRSS4P2RX1P2RX7P2RX4MEN1 | |
| SCHEMBL29781402 | 0.79 | P2RX1 (0.67) | TMPRSS4P2RX1P2RX7P2RX4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12503425-B2 | Methods of treating or controlling cytotoxic cerebral edema | AEROMICS, INC. (US) | 2025-12-23 | — | — | US | disclosed |
| US-20240360077-A1 | METHODS | AEROMICS, INC. | 2024-10-31 | — | — | US | disclosed |
| US-11873266-B2 | Methods of treating or controlling cytotoxic cerebral edema consequent to an ischemic stroke | AEROMICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-20220081391-A1 | METHODS | AEROMICS, INC. | 2022-03-17 | — | — | US | disclosed |
| CN-109512805-B | Compounds for the treatment of aquaporin mediated diseases | 埃罗米克斯公司 | 2021-12-31 | — | — | CN | disclosed |
| US-11084778-B2 | Methods of treating cardiac edema, neuromyelitis optica, and hyponatremia | AEROMICS, INC. (US) | 2021-08-10 | — | — | US | disclosed |
| US-20180334424-A1 | METHODS | AEROMICS, INC. | 2018-11-22 | — | — | US | disclosed |
| EP-2846787-B1 | Compounds for use in the treatment of aquaporin-mediated diseases | AEROMICS INC (US) | 2018-08-29 | — | — | EP | disclosed |
| US-9994514-B2 | Methods of treating cerebral edema and spinal cord edema | AEROMICS, INC. (US) | 2018-06-12 | — | — | US | disclosed |
| US-9949991-B2 | Methods of treating aquaporin-mediated conditions | AEROMICS, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-20060111409-A1 | Medicament for treatment of diabetes | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-05-25 | — | — | US | disclosed |
| US-20060100257-A1 | Inhibitors against the activation of ap-1 and nfat | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-05-11 | — | — | US | disclosed |
| US-20060019958-A1 | Immunity-related protein kinase inhibitors | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-01-26 | — | — | US | disclosed |
| US-20060014811-A1 | Medicament for treatment of cancer | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-01-19 | — | — | US | disclosed |
| EP-1514544-A1 | ANTIALLERGIC | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-16 | — | — | EP | disclosed |
| EP-1512396-A1 | INHIBITORS AGAINST THE ACTIVATION OF AP-1 AND NFAT | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-09 | — | — | EP | disclosed |
| EP-1510207-A1 | THERAPEUTIC DRUG FOR DIABETES | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-02 | — | — | EP | disclosed |
| EP-1510210-A1 | IMMUNITY-RELATED PROTEIN KINASE INHIBITORS | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-02 | — | — | EP | disclosed |
| US-20040259877-A1 | Inhibitors against the production and release of inflammatory cytokines | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2004-12-23 | — | — | US | disclosed |
| EP-1352650-A1 | INHIBITORS AGAINST THE PRODUCTION AND RELEASE OF INFLAMMATORY CYTOKINES | Institute of Medicinal Molecular Design, Inc. (JP) | 2003-10-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060019958-A1 | Immunity-related protein kinase inhibitors | MAP3K1, MAP3K7, MAP3K8 | TMPRSS4 3777/4885P2RX1 3942/4885P2RX7 3591/4885 |
| US-20180334424-A1 | METHODS | AQP4, AQP1, AQP3 | TMPRSS4 1257/4885P2RX1 2910/4885P2RX7 2817/4885 |
| US-12503425-B2 | Methods of treating or controlling cytotoxic cerebral edema | AQP4, AQP1, AQP3 | TMPRSS4 1043/4885P2RX1 2714/4885P2RX7 2687/4885 |
| US-20060111409-A1 | Medicament for treatment of diabetes | XDH, SLC5A1, SLC5A2 | TMPRSS4 3657/4885P2RX1 3455/4885P2RX7 3383/4885 |
| US-20220081391-A1 | METHODS | AQP4, AQP1, AQP3 | TMPRSS4 1257/4885P2RX1 2910/4885P2RX7 2817/4885 |
| US-20060014811-A1 | Medicament for treatment of cancer | HDAC3, HDAC1, HDAC6 | TMPRSS4 3353/4885P2RX1 4850/4885P2RX7 4811/4885 |
| US-11084778-B2 | Methods of treating cardiac edema, neuromyelitis optica, and hyponatremia | AQP4, AQP1, AQP3 | TMPRSS4 946/4885P2RX1 2805/4885P2RX7 2680/4885 |
| US-20060100257-A1 | Inhibitors against the activation of ap-1 and nfat | NFATC1, AP1G1, ATF1 | TMPRSS4 3386/4885P2RX1 3156/4885P2RX7 3197/4885 |
| US-11873266-B2 | Methods of treating or controlling cytotoxic cerebral edema consequent to an ischemic stroke | AQP4, AQP1, AQP3 | TMPRSS4 1444/4885P2RX1 3317/4885P2RX7 3316/4885 |
| US-20040259877-A1 | Inhibitors against the production and release of inflammatory cytokines | NFKBIA, IL1B, IKBKB | TMPRSS4 3292/4885P2RX1 2316/4885P2RX7 1605/4885 |
| US-20240360077-A1 | METHODS | AQP4, AQP1, AQP3 | TMPRSS4 1415/4885P2RX1 2797/4885P2RX7 2653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.